Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...
Reports FY24 revenue $36.13M, consensus $37.63M. “We believe that petosemtamab’s receipt of two Breakthrough Therapy designations by the FDA – ...
Hosted on MSN1d
Cancer treatment costs: 'I had to rob money from the money we’d set aside for my son’s wedding'Cover for high-cost cancer drugs, including Pembrolizumab, is subject to pre-authorisation and a case-by-case review, ...
The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the ...
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...
Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.
A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback